Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade
The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic...
Main Authors: | Chan, T.A (Author), Chowell, D. (Author), Morris, L.G.T (Author), Valero, C. (Author), Yoo, S.-K (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Research
2022
|
Online Access: | View Fulltext in Publisher |
Similar Items
-
Predictive biomarkers for tumor immune checkpoint blockade
by: Tong M, et al.
Published: (2018-10-01) -
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
by: Elisa Peranzoni, et al.
Published: (2020-07-01) -
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
by: Qingyang Xiao, et al.
Published: (2020-01-01) -
Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
by: Yanna Lei, et al.
Published: (2021-03-01) -
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
by: Cristina Valero, et al.
Published: (2021-02-01)